2025 ASH | 强生公布 CD19/CD20 双靶点 CAR-T 1b 期最新临床进展与生物标志物分析!

医麦客
Dec 24, 2025

2025 年 12 月 24 日医麦客新闻 eMedClub News本月 9 日,强生在第 65 届美国血液学会(ASH)年会上以口头报告形式,更新了其双靶点 CAR-T 疗法 Prizlo-cel(JNJ-90014496)的 1b 期临床试验数据及生物标志物关联分析。这一管线源自强生与西比曼 2023 年达成的全球合作,而强生官网更将其纳入“年销售峰值超 50 亿美元”的重磅管线矩阵。6 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10